The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
News|Articles|May 28, 2020
Almac Group Receives Grant for COVID-19 Clinical Study
Author(s)Pharmaceutical Technology Editors
The company has received a $288,000 grant from the COVID-19 Therapeutics Accelerator, part of the Bill & Melinda Gates Foundation, to support a clinical study in Sub-Saharan Africa to find a treatment for COVID-19.
Advertisement
Almac Group, a contract development and manufacturing organization, announced on May 28, 2020 that it has received a $288,000 grant from the COVID-19 Therapeutics Accelerator, part of the Bill & Melinda Gates Foundation, to support a clinical study in Sub-Saharan Africa to find a treatment for COVID-19.
According to a company press release, Almac Clinical Services will offer clinical trial solutions from protocol through to patient delivery and will ship all supplies to the clinical site, while Almac Sciences will provide analytical support from the company’s Craigavon, Northern Ireland headquarters. Additionally, the company will support a second, open-label clinical study through the distribution of commercial packs to a pharmacy in South Africa.
“This virus is threatening peoples’ lives and livelihoods and nowhere worse than in the poorer regions of the world,” said Dr. Robert Dunlop, managing director and president, Almac Clinical Services, in the press release. “Almac’s global capabilities and expertise enable us to play our part and support efforts to find a vaccine and/or treatment for coronavirus. We are delighted to be awarded this grant from the COVID-19 Therapeutics Accelerator and to be supporting these clinical studies in Sub-Saharan Africa.”
Source:
Advertisement
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement